Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSND-201
- Development stage
- Phase 3
- Lead developer
- Transcend Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
TSND-201 is a proprietary, rapid-acting neuroplastogen formulation of methylone developed by Transcend Therapeutics. It is designed as a non-hallucinogenic analog of MDMA and acts primarily as a triple reuptake inhibitor and releaser at the monoamine transporters—serotonin, norepinephrine, and dopamine—without activity at the 5HT-2a receptor. This mechanism distinguishes it from classic psychedelics. TSND-201 has demonstrated rapid, robust, and durable efficacy in reducing symptoms of post-traumatic stress disorder (PTSD) in clinical trials, with significant improvements observed within days after dosing. The drug is being developed for PTSD and other central nervous system (CNS) disorders such as major depressive disorder (MDD). Clinical studies have shown that TSND-201 can induce remission or significant symptom reduction in a substantial proportion of patients with treatment-resistant PTSD[1][3][4][5][6][7].
- Other names
- methylone
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on TSND-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSND-201.